Date: 23 Dec 2012
- Gillian M. Keating
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The 5α-reductase inhibitor dutasteride and the α1-adrenergic receptor antagonist tamsulosin are available as a fixed-dose combination for use in men with symptomatic benign prostatic hyperplasia (BPH) and an enlarged prostate.
Dutasteride 0.5 mg/day plus tamsulosin 0.4 mg/day improved lower urinary tract symptoms (LUTS) to a significantly greater extent than dutasteride or tamsulosin alone in men with BPH, moderate to severe LUTS and an increased risk of disease progression, according to the results of the randomized, double-blind, multinational CombAT trial. The mean change from baseline in the total International Prostate Symptom Score was significantly greater with dutasteride plus tamsulosin than with dutasteride or tamsulosin alone after 2 years (primary endpoint) and 4 years of therapy.
After 4 years’ therapy in the CombAT trial, the time to first acute urinary retention or BPH-related surgery (primary endpoint) significantly favoured men with symptomatic BPH who were receiving dutasteride plus tamsulosin versus those receiving tamsulosin alone, with no significant difference between recipients of dutasteride plus tamsulosin and recipients of dutasteride alone.
In the CombAT trial, health-related quality of life and treatment satisfaction were improved to a significantly greater extent with dutasteride plus tamsulosin than with dutasteride or tamsulosin alone.
Combination therapy with oral dutasteride plus tamsulosin was generally well tolerated in patients with symptomatic BPH in the CombAT trial.
McVary KT, Roehrborn CG, Avins AL, et al. American Urological Association guideline: management of benign prostatic hyperplasia (BPH) [online]. Available from URL: http://www.auanet.org/content/clinical-practice-guidelines/clinical-guidelines.cfm?sub=bph [Accessed 2011 Nov 21]
Oelke M, Bachmann A, Descazeaud A, et al. The treatmtent of non-neurogenic male LUTS [online]. Available from URL: http://www.uroweb.org/gls/pdf/12_Male_LUTS.pdf [Accessed 2011 Nov 21]
National Institute for Health and Clinical Excellence. Lower urinary tract symptoms: the management of lower urinary tract symptoms in men. NICE clinical guideline 97 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/12984/48557/48557.pdf [Accessed 2011 Dec 8]
Miller J, Tarter TH. Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate. Clin Interv Aging 2009; 4: 251–8PubMed
GlaxoSmithKline. Jalyn (dutasteride and tamsulosin hydrochloride) capsules: US prescribing information [online]. Available from URL: http://us.gsk.com/products/assets/us_jalyn.pdf [Accessed 2011 Nov 17]
Barkin J. Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability. Patient Prefer Adhere 2011; 5: 483–90CrossRef
Naslund M, Eaddy MT, Hogue SL, et al. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery. Curr Med Res Opin 2009 Nov; 25 (11): 2663–9PubMed
GlaxoSmithKline UK. Combodart(dutasteride/tamsulosin) 0.5 mg/0.4mg hard capsule: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/22943/SPC/Combodart+0.5+mg+++0.4+mg+hard+capsules/ [Accessed 2012 Apr 26]
Matsushima H, Kamimura H, Soeishi Y, et al. Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans. Drug Metab Dispos 1998 Mar; 26 (3): 240–5PubMed
Miyazawa Y, Blum RA, Schentag JJ, et al. Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function. Curr Ther Res 2001 Sep; 62 (9): 603–21CrossRef
Clark R, Haberer L. The dual 5α-reductase inhibitor dutasteride is well tolerated and has no effect on the pharmacokinetic profiles of tamsulosin or terazosin when used in combination in healthy male volunteers [abstract no. 840]. Eur Urol Suppl 2005 Mar; 4 (3): 212CrossRef
Siami P, Roehrborn CG, Barkin J, et al. Combination therapy with dutasteride and tamsulosin in men with moderateto-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials 2007; 28 (6): 770–9PubMedCrossRef
Becher E, Roehrborn CG, Siami P, et al. The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study. Prostate Cancer Prostatic Dis 2009; 12 (4): 369–74PubMedCrossRef
Montorsi F, Roehrborn C, Garcia-Penit J, et al. The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study. BJU Int 2011; 107 (9): 1426–31PubMedCrossRef
Roehrborn CG, Siami P, Barkin J, et al. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Eur Urol 2009; 55 (2): 461–71PubMedCrossRef
Roehrborn CG, Barkin J, Siami P, et al. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. BJU Int 2011; 107 (6): 946–54PubMedCrossRef
Tubaro A, Roehrborn CG, Barkin J, et al. Clinical outcomes after combination therapy with dutasteride and tamsulosin in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4 year results from the randomized, double-blind, CombAT trial [poster]. 25th Congress of the European Association of Urology; 2010 Apr 16–20; Barcelona
Montorsi F, Henkel T, Geboers A, et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study. Int J Clin Pract 2010 Jul; 64 (8): 1042–51PubMedCrossRef
Montlleó González M, Geiges G, Cicalese V, et al. Combination therapy with dutasteride plus tamsulosin reduces medical resource utilisation in men with benign prostatic hyperplasia: 4-year data from the CombAT study [abstract plus poster]. 25th Congress of the European Association of Urology; 2010 Apr 16–20; Barcelona
Andriole GL, Bostwick D, Brawley OW, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol 2011 Jan; 185 (1): 126–31PubMedCrossRef
Drugs & Aging
Volume 29, Issue 5 , pp 405-419
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand